Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
ZOLINZA |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Histone deacetylase inhibitor. |
| Generic Name |
|
Vorinostat 100mg; caps. |
| Indications |
|
Refractory cutaneous T-cell lymphoma. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated. |
| Precautions |
|
Congenital long QT syndrome. Hepatic impairment. Monitor for DVT, pulmonary embolism. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1st 2 months, then monthly. Do baseline and periodic ECGs. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid). Caution with other drugs that can cause QTc prolongation. Monitor warfarin. |
| Adverse Reactions |
|
GI upset, fatigue, chills; thrombocytopenia, anemia (may need to modify dose or discontinue); anorexia, dysgeusia, pulmonary embolism, DVT, QTc prolongation, hyperglycemia. |
| How Supplied |
|
Caps—120 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
